Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 69, Issue 12, 2012, Pages 1044-1048

  Patel, Manav B ^a   Elmore, Lindsey K ^b   Edgerton, Lisa P ^a   Whalin, Laurie M ^a  

^a NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^b SAMFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EXENDIN 4; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; LISINOPRIL; LOSARTAN; METFORMIN; SITAGLIPTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; COUGHING; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF MONITORING; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 84862886873     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110567     Document Type: Article

References (23)

1. Zander M, Madsbad S, Madsen JL et al. Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359:824-30. (Pubitemid 34233752)
2. Meier JJ, Gallwitz B, Salmen S et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagonlike peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88:2719-25. (Pubitemid 36733545)
3. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999; 22:1137-43. (Pubitemid 29293967)
4. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24:275-86. (Pubitemid 351160260)
5. Amylin Pharmaceuticals, Inc. Byetta (exenatide) package insert. San Diego, CA; 2009. http://pi.lilly.com/us/byetta-ppi.pdf (accessed 2010 Oct 20).
6. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta), October 2007. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124712.htm (accessed 2010 Oct 20).
7. Raz I, Hanefeld M, Xu L et al., for the Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49:2564-71.
8. Aschner P, Kipnes MS, Lunceford JK et al., for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29: 2632-7. (Pubitemid 44912190)
9. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28:1556-68. (Pubitemid 44841980)
10. Scott R, Wu M, Sanchez M et al. Efficacy and tolerability of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007; 61:171-80.
11. Merck & Co., Inc. Januvia (sitaglipitin) package insert. Whitehouse Station, NJ; 2006.
12. Food and Drug Administration. Information for healthcare professionals: acute pancreatitis and sitagliptin, September 25 2009. www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm (accessed 2010 Oct 31).
13. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.
14. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15:540-59. [Erratum, Endocr Pract. 2009; 15:768-70.]
15. Gutzwiller JP, Göke B, Drewe J et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999; 44:81-6. (Pubitemid 29143284)
16. Mannucci E, Ognibene A, Cremasco F et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obesity patients with type 2 diabetes mellitus. Diabet Med. 2000; 17:713-9.
17. Hsieh J, Longuet C, Baker CL et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010; 53:552-61.
18. Bulotta A, Perfetti R, Hui H et al. GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. J Lipid Res. 2003; 44:1559-65. (Pubitemid 37279601)
19. Tremblay AJ, Lamarche B, Deacon CF et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13:366-73.
20. Horton ES, Silberman C, Davis KL et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33:1759-65.
21. Bunck MC, Diamant M, Eliasson B et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010; 33:1734-7.
22. Okita M, Hayashi M, Sasagawa T et al. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition. 2001; 17:542-7. (Pubitemid 32633783)
23. Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008; 30:1448-60. [Erratum, Clin Ther. 2008; 30:1937.]